SCHEMBL1474031

SCHEMBL1474031

O=C(c1cc(-c2cccs2)on1)N1CCN(c2ccccn2)CC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.72
MAPT P10636 4/20 0.72
MAPK1 P28482 2/20 0.72
ALOX15 P16050 1/20 0.72
ALDH1A1 P00352 9/20 0.66
SMN1; SMN2 Q16637 4/20 0.66
HPGD P15428 4/20 0.66
NPC1 O15118 3/20 0.66
RAB9A P51151 3/20 0.66
TP53 P04637 1/20 0.66
TSHR P16473 4/20 0.66
CYP1A2 P05177 1/20 0.66
CYP3A4 P08684 1/20 0.66
CYP2C9 P11712 1/20 0.66
CYP2C19 P33261 1/20 0.66
PAX8 Q06710 1/20 0.62
NPSR1 Q6W5P4 1/20 0.62
KDM4E B2RXH2 3/20 0.56
HSD17B10 Q99714 3/20 0.56
CASP1 P29466 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1477294 0.88 LMNA (0.73) LMNAMAPTMAPK1ALOX15ALDH1A1
SCHEMBL4283450 0.81 RAB9A (0.79) LMNAMAPTMAPK1ALOX15ALDH1A1
SCHEMBL4288302 0.81 NPC1 (0.97) LMNAMAPTMAPK1ALOX15ALDH1A1
SCHEMBL2526391 0.80 NPC1 (1.00) LMNAMAPTMAPK1ALOX15ALDH1A1
SCHEMBL4286617 0.80 NPC1 (1.00) LMNAMAPTMAPK1ALOX15ALDH1A1
SCHEMBL4286780 0.79 RAB9A (0.79) LMNAMAPTMAPK1ALOX15ALDH1A1
SCHEMBL4278767 0.79 RAB9A (1.00) LMNAMAPTMAPK1ALOX15ALDH1A1
SCHEMBL9911613 0.78 RAB9A (0.77) LMNAMAPTMAPK1ALOX15ALDH1A1
SCHEMBL4280051 0.76 SMN1; SMN2 (0.73) LMNAMAPTMAPK1ALOX15ALDH1A1
SCHEMBL4280282 0.76 RAB9A (0.69) LMNAMAPTMAPK1ALOX15ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP claimed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US claimed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP claimed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO claimed
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP disclosed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO disclosed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 LMNA 2934/4885MAPT 2497/4885MAPK1 1608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.